Endothelial dysfunction: Does it matter? Is it reversible?

Journal of the American College of Cardiology

Volumn 30, Issue 2, 1997, Pages 325-333

  Celermajer, David S ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CORONARY ARTERY CONSTRICTION; FIBRINOLYSIS; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0030854730     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00189-7     Document Type: Article

References (116)

1. Petty RG, Pearson JD. Endothelium - the axis of vascular health and disease. J R Coll Physicians. 23:1989;92-101.
2. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 22:(Suppl 4):1993;S1-14.
3. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide physiology, pathophysiology, and pharmacology . Pharmacol Rev. 43:1991;109-142.
4. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
5. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 315:1986;1046-1051.
6. Gordon JB, Ganz P, Nabel EG, et al. Atherosclerosis and endothelial function influence the coronary vasomotor response to exercise. J Clin Invest. 83:1989;1946-1952.
7. Healy B. Endothelial cell dysfunction an emerging endocrinopathy linked to coronary disease . J Am Coll Cardiol. 16:1990;357-358.
8. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340:1992;1111-1115.
9. Cooke JP, Tsao PS. Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb. 14:1994;653-655.
10. Palade GE. Fine structure of blood capillaries. J Appl Physiol. 24:1953;1424-1430.
11. Gimbrone MA. Culture of vascular endothelium. Prog Hemost Thromb. 3:1976;1-28.
12. Jaffe EA. Biology of Endothelial Cells. 1984;Martinus Nijhoff, Boston.
13. Renkin EM. Multiple pathways of capillary permeability. Circ Res. 41:1977;735-743.
14. Machovich R. Choices among the possible reaction routes catalysed by thrombin. Ann N Y Acad Sci. 485:1986;170-183.
15. Esmon NL. Thrombomodulin. Semin Thromb Hemost. 13:1987;454-463.
16. 2) by layers of the arterial wall an explanation for the anti-thrombotic properties of vascular endothelium . Thromb Res. 11:1977;323-344.
17. Moncada S. Biological importance of prostacyclin. Br J Pharmacol. 76:1982;3-31.
18. Jaffe EA. Cell biology of endothelial cells. Hum Pathol. 18:1987;234-239.
19. Pearson JD, Gordon JL. Nucleotide metabolism by endothelium. Annu Rev Physiol. 47:1985;617-627.
20. Hekman CM, Loskutoff DJ. Fibrinolytic pathways and the endothelium. Semin Thromb Hemost. 13:1987;514-527.
21. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
22. Vanhoutte PM. Endothelium and control of vascular function. Hypertension. 13:1989;658-667.
23. Ryan JW, Ryan US. Endothelial surface enzymes and the dynamic processing of plasma substrates. Int Rev Exp Pathol. 26:1984;1-43.
24. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesise nitric oxide from L-arginine. Nature. 333:1988;664-666.
25. Vallance P, Collier J, Moncada S, et al. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 2:1989;103-110.
26. Celermajer DS, Dollery C, Burch M, Deanfield JE. Role of endothelium in the maintenance of low pulmonary vascular tone in normal children. Circulation. 89:1994;2041-2044.
27. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 89:1994;2035-2040.
28. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension. 8:1986;37-44.
29. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci. 74:1977;3203-3207.
30. Griffith TM, Edwards DH, Lewis MJ, Newby AC, Henderson AH. The nature of endothelium-derived relaxant factor. Nature. 308:1984;645-647.
31. Collins P, Griffith TM, Henderson AH, Lewis MJ. Endothelium-derived relaxing factor alters calcium fluxes in rabbit aorta a cyclic guanosine monophosphate-mediated effect . J Physiol (Lond). 381:1986;427-437.
32. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine smooth muscle. Br J Pharmacol. 93:1988;515-524.
33. Taylor SG, Weston AH. Endothelium-derived hyperpolarizing factor a new endogenous inhibitor from the vascular endothelium . Trends Pharmacol Sci. 9:1988;272-274.
34. FitzGerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest. 68:1981;1272-1275.
35. Masaki T. The discovery, the present state, and the future prospects of endothelin. J Cardiovasc Pharmacol. 13:(Suppl 5):1989;S1-S4.
36. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta inhibition by endothelium-derived nitric oxide . J Clin Invest. 85:1990;587-590.
37. Anggard E, Galton S, Rae G, et al. The fate of radio-iodinated endothelin-1 and endothelin-3 in the rat. J Cardiovasc Pharmacol. 13:(Suppl 5):1989;S46-S49.
38. Davenport AP, Ashley MJ, Easton P, et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma comparison of levels in patients with essential hypertension and normotensive control subjects . Clin Sci. 78:1990;261-264.
39. Warrens AN, Cassidy MJD, Takahashi K, Ghatei MA, Bloom SR. Endothelin in renal failure. Nephrol Dial Transplant. 5:1990;418-422.
40. Cody RJ. The potential role of endothelin as a vasoconstrictor substrate in congestive heart failure. Eur Heart J. 13:1992;1573-1578.
41. Paulus WJ, Vantrimpont PJ, Shah AM. Paracrine coronary endothelial control of left ventricular function in humans. Circulation. 92:1995;2119-2126.
42. Drexler H, Zeiher AM. Endothelial function in human coronary arteries in vivo. Hypertension. 18:1991;II-90-II-99.
43. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans progressive endothelial dysfunction with different early stages of coronary atherosclerosis . Circulation. 83:1991;391-401.
44. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
45. Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changing blood flow an endothelium-dependent mechanism that fails in patients with atherosclerosis . J Am Coll Cardiol. 16:1990;349-356.
46. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.
47. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
48. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease . Circulation. 94:1996;258-265.
49. Sorensen KE, Celermajer DS, Spiegelhalter DJ, et al. Non-invasive measurement of human endothelium dependent arterial responses accuracy and reproducibility . Br Heart J. 74:1995;247-253.
50. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 91:1995;1314-1319.
51. Anderson TJ, Uehata A, Gerhard MD, et al. Close relationship of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 26:1995;1235-1241.
52. Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 86:1990;228-234.
53. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 323:1990;22-27.
54. Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest. 97:1996;1989-1994.
55. Levine GN, Frei B, Kouloukis SN, Gerhard MO, Keaney JFJ, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 93:1996;1107-1113.
56. Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s . Nature. 362:1993;801-809.
57. Clarkson TB, Weingard KW, Kaplan JR, Adams MR. Mechanisms of atherogenesis. Circulation. 76:(Suppl I):1987;I-20-I-28.
58. Moore S. Thromboatherosclerosis in normolipemic rabbits a result of continued endothelial damage . Lab Invest. 29:1973;478-487.
59. Reidy MA, Schwartz SM. A technique to investigate surface morphology and endothelial cell replication of small arteries a study in acute angiotensin-induced hypertension . Microvasc Res. 24:1982;158-167.
60. DeGroot PG, Willems C, Boers GHJ, et al. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest. 13:1983;405-410.
61. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell. Science. 180:1973;1332-1339.
62. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 15:1995;551-561.
63. Steinberg DS. Lipoproteins and the pathogenesis of atherosclerosis. Circulation. 76:1987;508-514.
64. Henderson AH. Endothelium in control. Br Heart J. 65:1991;116-125.
65. Castellot J, Addonizo ML, Rosenberg R, et al. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J Cell Biol. 90:1981;372.
66. Stiles CD. The molecular biology of platelet-derived growth factor. Cell. 33:1983;653-655.
67. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 91:1993;2546-2551.
68. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 90:1992;1168-1172.
69. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol. 26:1995;1054-1061.
70. Adams MR, Jessup W, Celermajer DS. Cigarette smoking is associated with increased monocyte adhesion to endothelial cells in humans reversibility with L-arginine but not vitamin C . J Am Coll Cardiol. 29:1997;491-497.
71. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest. 93:1994;50-55.
72. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 88:1993;2149-2155.
73. Celermajer DS, Adams MR, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med. 334:1996;150-154.
74. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans effects of age, atherosclerosis, hypercholesterolemia, and hypertension . J Clin Invest. 92:1993;652-662.
75. Egashira K, Inou T, Hirooka Y, et al. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation. 88:1993;77-81.
76. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 24:1994;471-476.
77. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo blunted response in essential hypertension . Circulation. 81:1990;1762-1767.
78. Panza JA, Quyyumi AA, Brush JE Jr., Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 323:1990;22-27.
79. Calver A, Collier J, Moncada S, Vallance P. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension the nitric oxide dilator mechanism appears abnormal . J Hypertens. 10:1992;1025-1031.
80. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med. 330:1994;1036-1040.
81. Yokokawa K, Tahara H, Kohno M, et al. Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann Intern Med. 114:1991;213-215.
82. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 24:1994;1468-1474.
83. McLenachan JM, Vita J, Fish RD, et al. Early evidence of endothelial vasodilator dysfunction at coronary branch points. Circulation. 82:1990;1169-1173.
84. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 80:1987;1808-1811.
85. Fish RD, Nabel EG, Selwyn AP, et al. Responses of coronary arteries of cardiac transplant patients to acetylcholine. J Clin Invest. 81:1988;21-31.
86. Yeung AC, Vekshtein VI, Krantz DS, et al. The effects of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 325:1991;1551-1556.
87. Nabel EG, Selwyn AP, Ganz P. Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation. 81:1990;850-859.
88. McFadden EP, Clarke JG, Davies GJ, Kaski JC, Haider AW, Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med. 324:1991;648-654.
89. Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation. 81:1990;1586-1593.
90. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 338:1991;1546-1550.
91. Zeiher AM, Krause T, Schachinger V, Minners J, Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation. 91:1995;2345-2352.
92. El Tamimi H, Mansour M, Wargovich TJ, et al. Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease. Circulation. 89:1994;45-51.
93. Barbee KA, Mundel T, Lal R, Davies PF. Subcellular distribution of shear stress at the surface of flow-aligned and nonaligned endothelial monolayers. Am J Physiol. 268:1995;H1765-H1772.
94. Van Boven AJ, Jukema JW, Zwinderman AH, Crijins HJGM, Lie KI, Bruschke AVG. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 94:1996;1503-1505.
95. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 95:1997;324-328.
96. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
97. Sacks FM, Pfeffer MA, Moye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
98. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy the Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group . Ann Intern Med. 119:1993;969-976.
99. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
100. Chesebro JH, Lam JY, Badimon L, Fuster V. Restenosis after arterial angioplasty a hemorrheologic response to injury . Am J Cardiol. 60:1987;10B-16B.
101. Von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion in vivo transfer of endothelial cell nitric oxide synthase gene . Proc Natl Acad Sci USA. 92:1995;1137-1141.
102. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
103. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 341:1993;1496-1500.
104. Creager MA, Gallagher SH, Girerd XJ, Coleman S, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 90:1992;1248-1253.
105. Jeremy RW, McCarron H, Sullivan D. Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilation in the hypercholesterolemic rabbit. Circulation. 94:1996;498-506.
106. Aji W, Ravalli S, Szabolcs M, et al. L-Arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation. 95:1997;430-437.
107. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction. Circulation. 94:1996;240-243.
108. Dohi Y, Criscione L, Pfeiffer K, Luscher TF. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension studies in perfused mesenteric resistance arteries . J Cardiovasc Pharmacol. 24:1994;372-379.
109. Frielingsdorf J, Seiler C, Kaufmann P, Vassalli G, Suter T, Hess OM. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation. 93:1996;1380-1387.
110. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 89:1994;2545-2551.
111. Collins P, Rosano GM, Sarrel PM, et al. 17-Beta-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation. 92:1995;24-30.
112. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 121:1994;936-941.
113. McCrohon JA, Adams MR, McCredie RJ, et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin Endocrinol (Oxf). 45:1996;435-441.
114. Gerhard MD, Tawakol A, Halley EA. Long-term estradiol therapy with or without progesterone improves endothelium dependent vasodilatation in post-menopausal women [abstract]. Circulation. 94:(Suppl I):1996;I-279.
115. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure Collaborative Group on ACE Inhibitor Trials . JAMA. 273:1995;1450-1456.
116. Kwiterovich PO Jr. Diagnosis and management of familial dyslipoproteinemia in children and adolescents current issues in pediatric and adolescent endocrinology . Pediatr Clin North Am. 37:1990;1489-1523.